Johnson & Johnson and its U.S.-based subsidiary Janssen have reached a settlement agreement with the State of New Hampshire to resolve opioid allegations.  J&J will pay $39 million and an additional roughly $1.5 million to New Hampshire under the deal, which relates to a suit filed in 2018. New Hampshire will be reimbursed for the…

Johnson & Johnson (NYSE:JNJ) announced today that it completed an agreement for the manufacturing of its COVID-19 vaccine in Africa. The landmark agreement, made between Johnson & Johnson’s Janssen Pharmaceuticals and South Africa-based Aspen SA Operations, allows for the first COVID-19 vaccine to be manufactured and made available by an African company for people living…

Johnson & Johnson (NYSE:JNJ) has decided to temporarily suspend production of its COVID-19 vaccine in Leiden in the Netherlands to prioritize production of an investigational respiratory syncytial virus (RSV) vaccine, according to The New York Times. The plant will resume production of its COVID-19 vaccine in a matter of months, the paper reported. The company is…

Johnson & Johnson (NYSE:JNJ) has announced that it is collaborating with academic institutions internationally to gauge the effectiveness of its COVID-19 vaccine against Omicron and other SARS-CoV-2 variants. In particular, J&J said it is conducting research on blood serum from clinical trial volunteers who have received single or multiple doses of its COVID-19 vaccine. The…

COVID-19 vaccine booster eligibility has gradually expanded, but a significant portion of adults don’t meet the current criteria set forth by FDA and CDC. California and Colorado have decided to sidestep the federal government by making all fully vaccinated adults in those states eligible for a booster. California will require that six months have elapsed…

Recently, General Electric (NYSE:GE), Zimmer Biomet (NYSE: ZBH) and Toshiba (TYO:6502) announced their plans to slim down by spinning out core businesses. Now, Johnson & Johnson (NYSE:JNJ) is following a similar approach by making its consumer health business a standalone company. J&J will retain its pharmaceutical and medical device segments. The company said in an…

As a growing number of Americans become eligible for a third dose of COVID-19 vaccines, CDC continues to expand its booster guidelines. The agency has amended its criteria for moderately to severely immunocompromised people to allow a fourth dose of COVID-19 vaccine six months after receiving the third dose. The criteria pertain to immunocompromised individuals…

Drawing from de-identified insurance claims data, Johnson & Johnson (NYSE:JNJ) has announced that a single dose of its Ad26.COV2.S vaccine was 79% effective in preventing COVID-19 infections and is 81% effective in preventing hospitalizations associated with the novel coronavirus. The company also released results from its Phase 3 ENSEMBLE 2 trial, which tested the impact…

Initially facing a shortage of COVID-19 vaccines, Canada has now vaccinated a greater share of its population than the U.S. Now, the country is planning on donating 10 million doses to low- and middle-income countries via the COVAX initiative, a global program that aims to distribute vaccines in developing nations. The country had faced controversy…

The United Kingdom announced that it approved the single-dose COVID-19 vaccine developed by Johnson & Johnson’s Janssen Pharmaceutical business. The Medicines and Healthcare products Regulatory Agency (MHRA) granted the regulatory approval, making Janssen’s the fourth COVID-19 vaccine authorized by the independent regulator and the first to be approved as a single-dose option, according to a…